ST凯利：前三季度报告中营业收入包含了骨水泥产品的相关收入

Core Insights - The company has confirmed that its bone cement business is a significant part of its minimally invasive vertebroplasty operations, and revenue from bone cement products will be included in the financial report for the first three quarters of 2025 [1] - The company's operations are primarily focused on orthopedics, and it has divested its stake in Jianuo Medical Management Group, which means that related revenue from this entity will no longer be included in the consolidated financial statements [1] Company Operations - The bone cement business is an important component of the company's minimally invasive procedures [1] - As of the board meeting on August 4, 2025, the company approved the sale of its stake in Jianuo Medical Management Group and the reduction of its investment in Shanghai Jingzheng Medical Technology Co., Ltd [1] - Following the completion of this divestiture, the company will no longer hold shares in Jianuo Medical and its subsidiaries, thus excluding their revenue from future consolidated reports [1]